Cardiopoietic stem cell therapy in ischaemic heart failure: long ‐term clinical outcomes
ConclusionsLongitudinal follow ‐up documents that cardiopoietic stem cell therapy is overall safe, and post hoc analyses suggest benefit in an ischaemic heart failure subpopulation defined by advanced left ventricular enlargement on tolerable stem cell dosing. The long‐term clinical follow‐up thus offers guidance for future targeted trials.
Source: ESC Heart Failure - Category: Cardiology Authors: Jozef Bartunek,
Andre Terzic,
Beth A. Davison,
Atta Behfar,
Ricardo Sanz ‐Ruiz,
Wojciech Wojakowski,
Warren Sherman,
Guy R. Heyndrickx,
Marco Metra,
Gerasimos S. Filippatos,
Scott A. Waldman,
John R. Teerlink,
Timothy D. Henry,
Bernard J. G Tags: Original Research Article Source Type: research
More News: Cardiology | Cardiovascular | Congestive Heart Failure | Eyes | Heart | Heart Failure | Stem Cell Therapy | Stem Cells | Study